In addition, the expression of EGFR variant III (EGFRvIII) is tumor restricted, and it has been reported that EGFRvIII-specific CAR-T cells have reduced immune exhaustion and enhanced anti-glioma therapeutic function with a lower risk of on-target/off-tumor toxicity mediated by the CAR recognizing antigens on normal tissue (93). Here, EGFR is linked to neoplasm.